Fundraising Fox
Akston Biosciences
Beverly, US · Delaware corporation · 2 known investors
Find your way into Akston Biosciences
Each arrow is one introduction. Sign up to fill in the first one.
537 people can intro you to Todd
Ask Rahul Bhansali to introduce you to Todd Zion
You →Rahul · together at Akston Biosciences →Todd
Sign up to find every way you can get introduced to Akston Biosciences
- Your email: who you already know at Akston Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Akston Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Akston Biosciences develops protein-based therapies for pets to support veterinary care and improve treatment accessibility. The company focuses on pet-focused biotechnology aimed at making animal therapies more affordable for pet owners.
Founders & leadership
TC
Todd C. ZionCo-founder, President & CEOTodd Zion holds a Ph.D. in Chemical Engineering from MIT and a B.S. in Chemical Engineering from Cornell University. He founded and served as President and CEO of SmartCells, Inc., which developed glucose-responsive insulin technology and was acquired by Merck in 2010, and is co-founder and CEO of Akston Biosciences, a developer of protein-based therapies for veterinary applications.
JH
James HerrimanNamed on SEC filing
RD
Robyn DavisNamed on SEC filing
LE
Lovick E. CannonNamed on SEC filing
TM
Thomas M. LancasterNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.7M disclosed across 5 of 6 rounds · 2019–2026
▶$5.2MraisedApr 2022 · 37 investors · BiotechnologyRule 506(b)
▶$5.2MraisedApr 2022 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HerrimanExecutive Officer
- Thomas M. LancasterExecutive Officer, Director
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Robyn DavisDirector
- Offering amount
- $10M
- Amount sold
- $5.2M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.9MraisedJun 2021 · 71 investors · BiotechnologyRule 506(b)
▶$7.9MraisedJun 2021 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Thomas M. LancasterExecutive Officer, Director
- James HerrimanExecutive Officer
- Robyn DavisDirector
- Offering amount
- $8M
- Amount sold
- $7.9M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJun 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HerrimanExecutive Officer
- Robyn DavisDirector
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Thomas M. LancasterExecutive Officer, Director
- Offering amount
- $11.8M
- Amount sold
- $1M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedMay 2020 · 71 investors · BiotechnologyRule 506(b)
▶$5.1MraisedMay 2020 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HerrimanExecutive Officer
- Thomas M. LancasterExecutive Officer, Director
- Todd C. ZionExecutive Officer, Director
- Lovick E. CannonDirector
- Robyn DavisDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJun 2019 · 46 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2019 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robyn DavisDirector
- James HerrimanExecutive Officer
- Thomas M. LancasterExecutive Officer, Director
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Offering amount
- $2.8M
- Amount sold
- $2.5M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $249.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $249.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Akston Biosciences do?
- Akston Biosciences develops protein-based therapies for pets to support veterinary care and improve treatment accessibility. The company focuses on pet-focused biotechnology aimed at making animal therapies more affordable for pet owners.
- Who founded Akston Biosciences?
- Akston Biosciences was founded by Todd C. Zion.
- Who are Akston Biosciences's investors?
- Akston Biosciences's investors include Boston Harbor Angels, Formation Venture Engineering.
- How much funding has Akston Biosciences raised?
- Akston Biosciences has disclosed $21.7M raised across 5 of its 6 known rounds.
- Where is Akston Biosciences headquartered?
- Akston Biosciences is headquartered in Beverly, US.